Driving a More Productive and Cost-Effective Drug Development Process
With increasing resource pressure, drug developers need to make more effective and informed go/no-go decisions as early as possible in the drug development process. This allows the best compounds to move ahead with adequate resource support. By doing more of the right experiments, drug developers will face fewer surprises as drugs move into the more expensive later stages of the development process. Biomarkers, advanced bio-imaging and other tools are increasingly being used as important approaches to creating more effective decision making processes. Leading drug discovery and development companies are increasingly reorganizing their drug development process and programs to take advantage of new tools and techniques to improve ROI on Drug Development dollars and focus resources on the most promising candidates.
Featured Speakers:
- Jan Van Gelder, Ph.D., Head,Preformulation, Eli Lilly and Company
- Charles Gombar, Ph.D., Vice President, R+D Strategy and Business Improvement, Wyeth Pharmaceuticals
- Victor Sandor, M.D., Global Product Head, Executive Director, Oncology, Clinical Development, AstraZeneca Pharmaceuticals
- Dongzhou (Jeffery) Liu, Ph.D., M.Sc., M.B.A., Assistant Director, New Products Research & Development, GlaxoSmithKline
- John Gilly, Ph.D., Deputy Director, Biopharmaceutical Development Program, SAICFrederick/ NCI-Frederick
Learn from Leading Practitioners How to Build a More Effective Drug Discovery and Development Process:
- Advanced Proof-of-Concept Tools and Approaches
- Moving Beyond the Phase Trial Model
- Measuring Targets, Pathways and Impacts
- Case Studies of New Proof-of-Concept Approaches and Programs
- Understanding Candidate “Mechanisms-of-Action”
- Risk-Sharing Models for Early Drug Development
- Implementing New Drug Development Process Models
- In-vitro and in-vivo Validation
Proof-of-Concept Tools, Techniques and Technologies:
- FDG-PET Imaging
- Biomarkers in Early Stage Drug Development
- Gene Expression Approaches and Case Studies
- Metabolomics Profiling
- Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI)
- Combination Protocols
- Magnetic Resonance Spectroscopy (MRS)
- Genetic Profiling to Stratify Patient Populations
- Pharmacokinetics
Scientific Advisory Committee:
Charles Gombar, Ph.D., Vice President, R+D Strategy and Business Improvement, Wyeth Pharmaceuticals
Paul L. Domanico, Ph.D., President, Paul Domanico Consulting, LLC
Mark Watson, Ph.D., Associate Director, Biology, Gemin X Pharmaceuticals Canada, Inc.
Stephen Donahue, M.D., Senior Vice President, Clinical Development, Ore Pharmaceuticals, Inc.
Geert Kolvenbag, Ph.D., M.D., Executive Director, Development, Emerging Oncology and Infection Brands, AstraZeneca Pharmaceuticals, Inc.
Co-located Event:
Drug Repositioning Summit
October 6-7, 2008 | Boston, Massachusetts
Click here for updated conference information
Discounted Joint Pricing Options Available!